A New Generation of Medicine

Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications
Download our Pitch Deck

The future of mental health and personal development is in psychedelics.

Pharmaceutical-Grade Products

All Psygen psychedelic products are of the highest quality, manufactured in our GMP compliant manufacturing facility.

Psychedelics for Clinical Research

Psygen’s mission is to accelerate the research and development of psychedelic drugs for medicinal and therapeutic applications.

Psygen's Social Mandate

We are committed to donating up to 10% of all profits to our charitable foundation to provide access to therapy for low income populations, fund non-profit research programs and fund environmental programs.

The Team

Chief Executive Officer

Danny Motyka

Danny graduated from the University of Victoria with a degree in chemistry before becoming an early employee at Aurora Cannabis. His career with Aurora provided foundational experience in enterprise management, good manufacturing practices, and the Controlled Drugs and Substances Act.
Chief Scientific Officer

Peter van der Heyden

Dr. van der Heyden’s scientific focus is on cGMP manufacture of lysergamides, tryptamines and phenethylamines for use in clinical trials, and on biotechnological approaches to assembling precursors and psychedelic drug molecules.
Clinical Research Advisor

Mark Haden

Mark Haden is Adjunct Professor of the UBC School of Population and Public Health. He is currently involved with the British Columbia Health Officers Council drug policy committee and provides public information on drugs and drug policy.

Request Research Material



Signup to our Newsletter